Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK receives marketing authorisation from the European Commission for additional indication: Tyverb™ (lapatinib)
GSK announced today that the EC has granted an additional indication for Tyverb™ (lapatinib) to be used in combination with trastuzumab.
-
ViiV Healthcare announces U.S. approval of Tivicay® (dolutegravir) for the treatment of HIV-1
ViiV Healthcare is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved Tivicay® (dolutegravir)
-
GSK launches 50 million venture capital fund to invest in pioneering bioelectronic medicines and technologies
GSK launch of Action Potential Venture, a $50 million strategic venture that will invest in companies that pioneer bioelectronic medicines
-
Regulatory Update - GSK announces EU submission seeking additional indication for Votrient® as maintenance therapy for advanced ovarian cancer
GSK today announced submission to the European Medicines Agency of a variation to the Marketing Authorisation for Votrient® (pazopanib)
-
Regulatory update – GSK announces EU submission for Cervarix® two dose schedule
GSK announced, submission of a regulatory application in the EU for two dosing schedule in 9-14yo girls for its cervical cancer vaccine.
-
Regulatory update: albiglutide US PDUFA date extended by three months
GSK announced that PDUFA goal date for albiglutide, treatment for adult patients with type 2 diabetes, has been extended by three months.
-
GSK adds to its commitment to GAVI Alliance to help protect millions more children against infectious diseases
Extension of Synflorix vaccine supply agreement will help protect an additional 80 million children in the world's poorest countries.
-
GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepatitis C infection
GSK announced a positive opinion from EMA's CHMP recommending marketing authorisation for Revolade™ (eltrombopag).
-
Results announcement for the second quarter 2013
GSK announces Q2 core EPS growth of 4% and dividend of 18p
-
GSK statement regarding recent meeting with Chinese authorities
with the Chinese Ministry of Public Security GSK Abbas Hussain, President International - made the following statement.
-
Update on GSK Consumer Nigeria plc Scheme of Arrangement
GSK announced shareholders document dated 24 June 2013, where it was proposed to increase ownership in GSK Nigeria to 75%, will be withdrawn
-
GSK response to China investigation
In response to the investigations by government authorities in China regarding our business in the country, GSK has issued a statement.
-
Regulatory update: fluticasone furoate/vilanterol submission in Japan
GSK & THRX announce application for FF and vilanterol in patients with COPD has been withdrawn from the Japanese New Drug Application (JNDA)
-
Regulatory update – GSK announces US submission for dabrafenib/trametinib combination in metastatic melanoma
GSK today announced submission of NDAs to the FDA for use of dabrafenib, a BRAF inhibitor, in combination with trametinib, a MEK inhibitor.
-
Regulatory Update - GSK receives positive CHMP opinions for Tafinlar® (dabrafenib) and Tyverb® (lapatinib)
GSK announces that the European Medicines Agency's CHMP is recommending marketing authorisation for two cancer drugs.
-
GSK and Save the Children launch $1 million award to discover new healthcare innovations for reducing child deaths
The Healthcare Innovation Award is the first joint initiative announced following the partnership between GSK and Save the Children
-
GlaxoSmithKline’s drisapersen (previously GSK2402968/PRO051) to receive Food and Drug Administration Breakthrough Therapy designation
Breakthrough Therapy designation is one of several programmes created by the FDA to expedite the development and review of drugs.
-
GSK announces data from five Phase III studies of albiglutide, an investigational once-weekly treatment for type 2 diabetes
Data from five long-term Phase III studies comparing albiglutide to placebo presented at the American Diabetes Association Meeting
-
GSK receives offer for its thrombosis brands and related manufacturing site
GSK has today received an offer for its thrombosis brands and NDB site from Aspen Global Incorporated and Aspen Pharmacare Holdings Limited.
-
GSK statement regarding 2010 Nature Medicine study
GSK and Nature Medicine aware of allegations of misrepresentation of data in research paper written by scientists at GSK's China centre
